Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

Executive Summary

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

You may also be interested in...



Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.

ASH Preview: Three Areas To Watch In Hematology-Oncology

Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.

Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors

Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel